Basilea Pharmaceutica (OTCMKTS:BPMUF) Stock Price Up 10.4% - Should You Buy?

Key Points

• Basilea Pharmaceutica AG shares experienced a significant increase of 10.4% during mid-day trading, reaching a last traded price of $67.75.
• The company has strong liquidity ratios, with a quick ratio of 4.16 and a current ratio of 4.85, indicating its ability to cover short-term obligations.
• Basilea focuses on developing oncology and anti-infective treatments, including their antifungal drug Cresemba for invasive aspergillosis and mucormycosis.

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) rose 10.4% on Wednesday . The company traded as high as $67.75 and last traded at $67.75. Approximately 15 shares traded hands during mid-day trading, The stock had previously closed at $61.34.

Basilea Pharmaceutica Price Performance

The business has a 50 day moving average price of $58.00 and a two-hundred day moving average price of $53.80. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.85 and a quick ratio of 4.16.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.